Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Share News (ERGO)

  • There is currently no data for ERGO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Midatech Pharma Appoints Former Ergomed CEO As Chief Financial Officer

Mon, 09th Sep 2019 12:20

(Alliance News) - Immunotherapy-focused pharmaceutical company Midatech Pharma PLC said Monday it has appointed Stephen Stamp as chief financial officer with immediate effect.

He will be replacing Nick Robbins-Cherry, who stepped down from his role after five years in the role since 2014. Robbins-Cherry will remain at Midatech until October to facilitate an orderly handover.

Stamp was most recently chief executive officer of pharmaceutical services firm Ergomed PLC for two years since 2017, stepping down in January due to health reasons. Prior to that he was chief financial officer at Ergomed for a year from 2016 to 2017.

Before then, he was chief financial officer of US-based personalised medicine group AssureRx Health Inc, for three years from 2013 to 2016.

In the past, Stamp was the finance director of office space provider Regus PLC and former London-listed pharmaceutical firm Shire PLC.

"The directors are delighted to welcome Stephen Stamp to the board of Midatech as CFO. He brings a wealth of relevant financial, commercial and industry experience gained in a wide range of senior roles at major healthcare companies, in the UK and internationally, which will enable him to make a significant contribution to Midatech's future success. This is an exciting time for the company and having someone of Stephen's financial pedigree joining will be a real asset," said Chair Rolf Stahel.

Shares in Midatech Pharma were untraded on Monday, last quoted at 5.59 pence in London.

More News
26 May 2016 08:40

BROKER RATINGS SUMMARY: Jefferies And Exane BNP Downgrade M&S

Read more
16 May 2016 08:13

Ergomed Issues Shares Under Bookrunner Option Exercises (ALLISS)

Read more
4 May 2016 11:50

Ergomed To Acquire Haemostatix, To Raise Up To GBP13 Million (ALLISS)

Read more
12 Apr 2016 08:11

Ergomed Profit More Than Doubles On Revenue And Margin Growth

Read more
6 Apr 2016 15:05

Earnings, Trading Statements Calendar - Week Ahead

Read more
5 Apr 2016 15:02

Earnings, Trading Statements Calendar - Week Ahead

Read more
1 Feb 2016 09:30

Ergomed Confident For 2016 And Beyond As 2015 Revenue Up 25%

Read more
11 Jan 2016 09:10

Ergomed Moves Finance Chief To New Role, Appoints New CFO

Read more
16 Dec 2015 10:58

Ergomed Says Co-Development Partnerships Pipeline On Track

Read more
21 Oct 2015 09:30

Ergomed Says Co-Development Partner Terminates Lung Cancer Trial

Read more
14 Oct 2015 10:20

Ergomed Partner Aeterna Zentaris To Continue Phase 3 ZoptEC Study

Read more
13 Oct 2015 10:03

Ergomed, Dilaforette Begin Phase II Sevuparin Trial

Read more
5 Oct 2015 12:14

Ergomed To Up Contribution To CEL-SCI Head And Neck Cancer Trial

Read more
29 Sep 2015 14:03

Ergomed doubles profits as contract revenues increase

(ShareCast News) - Ergomed has doubled its half year gross profit after increasing revenues from its clinical studies and pharmacovigilance contracts. The AIM-listed company, which provides specialised services to the pharmaceutical industry and develops new drugs, posted its half year results to 30

Read more
29 Sep 2015 11:22

Ergomed Confident In Outlook As First Half Profit Rises

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.